Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Anal Cell Pathol (Amst)
Main Authors: Yahiro, Kenichiro, Matsumoto, Yoshihiro, Fukushi, Jun-ichi, Kawaguchi, Ken-ichi, Endo, Makoto, Setsu, Nokitaka, IIda, Keiichiro, Fukushima, Suguru, Nakagawa, Makoto, Kimura, Atsushi, Oda, Yoshinao, Nakashima, Yasuharu
פורמט: Artigo
שפה:Inglês
יצא לאור: Hindawi 2018
נושאים:
Research Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6033248/
https://ncbi.nlm.nih.gov/pubmed/30034996
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/8987568
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים